Fig. 2.

The ligand–receptor interactions of the promising docked compounds; A: Naringenin-7-O-glucoside, B: 1-hydroxy-2-hydroxymethyl AQ, C: Palitantin, D: S-Adenosyl-L methioninamine, E: Thonningianin-A, F: Thonningianin-B, while other compounds (G-V) are drawn inside the active site of α-amylase inhibitor (PDB=1HX0), nitric oxide synthase (PBB=3E7G), BCL2 (PDB: 4IEH), EGFR (PDB 1M17), Protein kinase (1T46) and VEGFR-2 (1Y6A), CDK-2 (Lys 89), S. aureus Murb (PDBID: 1HSK) and aspartyl proteinase-5 (SAP5) (PDBID: 2QZX), DNA Gyrase (1KZN) and Topoisomerase VI (1S14), EGFR protein (A) and CDK-2 protein as previously published [69], [70], [71], [72], [73], [74], [75], [76], [77].